IcoSema vs Insulin glargine (Basaglar)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
IcoSema · Kyinsu
Marketed by Novo Nordisk
NCT05352815 · Phase 3 · completed
Participants were randomized 1:1 to IcoSema or active insulin icodec, but the study was open-label rather than blinded. The primary HbA1c endpoint was statistically significantly better with IcoSema, although HbA1c is a surrogate metabolic measure rather than a hard clinical endpoint.
Reported efficacy
Change in glycated haemoglobin (HbA1c) (From baseline (week 0) to week 40): (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001) (met)
Result source: NCT06269107
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | IcoSema | Insulin glargine (Basaglar) |
|---|---|---|
| HbA1c, change | -1.6% vs -0.9%vs Insulin IcodecNCT053528152 other results
| -1.3% vs -1.3%vs LantusNCT014214599 other results
|
| Body weight, change (kg) | -3.7 vs 2.0vs Insulin IcodecNCT053528151 other result
| 1.9 vs 2.2vs LantusNCT014214597 other results
|
| HbA1c below 7% | —Not posted · NCT05013229 | 43.7% vs 44.9%vs Lantus®NCT03338010 |
| Fasting plasma glucose, change | -1.9 vs -1.6vs Insulin IcodecNCT053528151 other result
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT05013229 | —Not reported |
HbA1c, change
- IcoSema
- -1.6% vs -0.9%vs Insulin IcodecNCT05352815
2 other results
- -1.4% vs -0.9% NCT05259033
- -1.5% vs -1.4% NCT05013229
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -0.5% vs -0.5% NCT01421459
Body weight, change (kg)
- IcoSema
- -3.7 vs 2.0vs Insulin IcodecNCT05352815
1 other result
- 0.9 vs -3.8 NCT05259033
- Insulin glargine (Basaglar)
- 1.9 vs 2.2vs LantusNCT01421459
7 other results
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 1.7 vs 2.2 NCT01421459
- 1.6 vs 1.9 NCT01421459
- 1.3 vs 1.4 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 0.3 vs 0.5 NCT01421459
HbA1c below 7%
- IcoSema
- —Not posted · NCT05013229
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
Fasting plasma glucose, change
- IcoSema
- -1.9 vs -1.6vs Insulin IcodecNCT05352815
1 other result
- -2.7 vs -1.4 NCT05259033
- Insulin glargine (Basaglar)
- —Not reported
3-point MACE (% with event)
- IcoSema
- —Not posted · NCT05013229
- Insulin glargine (Basaglar)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. IcoSema: 3 of 4 rows · Insulin glargine (Basaglar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | IcoSema | Insulin glargine (Basaglar) |
|---|---|---|
| Dropout rate | 5.4% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result3.8% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 11.9%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result— NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 1.6%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 9.2% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more result11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 4%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 23.8% diarrhoea 15.8% vomiting 10.6% NCT05352815 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 1 more resultcovid-19 15% nausea 11.7% diarrhoea 11.1% NCT05259033 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | a nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
IcoSema
show 1 more result
Insulin glargine (Basaglar)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IcoSema's landscape · Insulin glargine (Basaglar)'s landscape